Parthenolide inhibits STAT3 signaling and attenuates angiotensin II-induced left ventricular hypertrophy via modulation of fibroblast activity

Journal of Molecular and Cellular Cardiology

Volumn 50, Issue 4, 2011, Pages 634-641

  Skoumal, Réka ^a,b   Tóth, Miklós ^b   Serpi, Raisa ^a   Rysä, Jaana ^a   Leskinen, Hanna ^a   Ulvila, Johanna ^a   Saiho, Tarja ^a   Aro, Jani ^a   Ruskoaho, Heikki ^a   Szokodi, István ^c   Kerkelä, Risto ^a  

^a UNIVERSITY OF OULU   (Finland)

^b UNIVERSITY OF PHYSICAL EDUCATION   (Hungary)

^c UNIVERSITY OF PÉCS   (Hungary)

Author keywords

Fibrosis; Left ventricular hypertrophy; Parthenolide; Pressure overload; STAT3

Indexed keywords

ANGIOTENSIN II; COLLAGEN TYPE 1; FIBRONECTIN; INTERLEUKIN 6; PARTHENOLIDE; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; SERINE; STAT3 PROTEIN; TYROSINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; COLLAGEN SYNTHESIS; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; FIBROBLAST; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE OVERLOAD; HEART MUSCLE FIBROSIS; HEART RATE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT;

ANGIOTENSIN II; ANIMALS; BLOTTING, WESTERN; ECHOCARDIOGRAPHY; ELECTROPHORETIC MOBILITY SHIFT ASSAY; FIBROBLASTS; HEMODYNAMICS; HYPERTROPHY, LEFT VENTRICULAR; IMMUNOHISTOCHEMISTRY; MALE; PHOSPHORYLATION; RATS; RATS, SPRAGUE-DAWLEY; SESQUITERPENES; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

RATTUS;

EID: 79952071351     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2011.01.001     Document Type: Article

References (42)

1. Lorell B.H., Carabello B.A. Left ventricular hypertrophy: pathogenesis, detection, and prognosis. Circulation 2000, 102:470-479.
2. Hilfiker-Kleiner D., Hilfiker A., Drexler H. Many good reasons to have STAT3 in the heart. Pharmacol Ther 2005, 107:131-137.
3. Negoro S., Kunisada K., Fujio Y., et al. Activation of signal transducer and activator of transcription 3 protects cardiomyocytes from hypoxia/reoxygenation-induced oxidative stress through the upregulation of manganese superoxide dismutase. Circulation 2001, 104:979-981.
4. Hilfiker-Kleiner D., Hilfiker A., Fuchs M., et al. Signal transducer and activator of transcription 3 is required for myocardial capillary growth, control of interstitial matrix deposition, and heart protection from ischemic injury. Circ Res 2004, 95:187-195.
5. Kunisada K., Negoro S., Tone E., et al. Signal transducer and activator of transcription 3 in the heart transduces not only a hypertrophic signal but a protective signal against doxorubicin-induced cardiomyopathy. Proc Natl Acad Sci USA 2000, 97:315-319.
6. Osugi T., Oshima Y., Fujio Y., et al. Cardiac-specific activation of signal transducer and activator of transcription 3 promotes vascular formation in the heart. J Biol Chem 2002, 277:6676-6681.
7. Hirota H., Chen J., Betz U.A., et al. Loss of a gp130 cardiac muscle cell survival pathway is a critical event in the onset of heart failure during biomechanical stress. Cell 1999, 97:189-198.
8. Hilfiker-Kleiner D., Shukla P., Klein G., et al. Continuous glycoprotein-130-mediated signal transducer and activator of transcription-3 activation promotes inflammation, left ventricular rupture, and adverse outcome in subacute myocardial infarction. Circulation 2010, 122:145-155.
9. Yu H., Jove R. The STATs of cancer-new molecular targets come of age. Nat Rev Cancer 2004, 4:97-105.
10. Nakshatri H., Rice S.E., Bhat-Nakshatri P. Antitumor agent parthenolide reverses resistance of breast cancer cells to tumor necrosis factor-related apoptosis-inducing ligand through sustained activation of c-Jun N-terminal kinase. Oncogene 2004, 23:7330-7344.
11. Guzman M.L., Rossi R.M., Karnischky L., et al. The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Blood 2005, 105:4163-4169.
12. Aggarwal B.B., Sethi G., Ahn K.S., et al. Targeting signal-transducer-and-activator-of-transcription-3 for prevention and therapy of cancer: modern target but ancient solution. Ann NY Acad Sci 2006, 1091:151-169.
13. Guzman M.L., Rossi R.M., Neelakantan S., et al. An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. Blood 2007, 110:4427-4435.
14. Lako-Futo Z., Szokodi I., Sarman B., et al. Evidence for a functional role of angiotensin II type 2 receptor in the cardiac hypertrophic process in vivo in the rat heart. Circulation 2003, 108:2414-2422.
15. Sarman B., Skoumal R., Leskinen H., et al. Nuclear factor-kappaB signaling contributes to severe, but not moderate, angiotensin II-induced left ventricular remodeling. J Hypertens 2007, 25:1927-1939.
16. Tenhunen O., Rysa J., Ilves M., et al. Identification of cell cycle regulatory and inflammatory genes as predominant targets of p38 mitogen-activated protein kinase in the heart. Circ Res 2006, 99:485-493.
17. Vuolteenaho O., Koistinen P., Martikkala V., Takala T., Leppaluoto J. Effect of physical exercise in hypobaric conditions on atrial natriuretic peptide secretion. Am J Physiol 1992, 263:R647-R652.
18. Dahlof B., Devereux R.B., Kjeldsen S.E., Julius S., Beevers G. de FU et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359:995-1003.
19. Timmermans P.B., Wong P.C., Chiu A.T., et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993, 45:205-251.
20. Heineke J., Molkentin J.D. Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rev Mol Cell Biol 2006, 7:589-600.
21. Podewski E.K., Hilfiker-Kleiner D., Hilfiker A., et al. Alterations in Janus kinase (JAK)-signal transducers and activators of transcription (STAT) signaling in patients with end-stage dilated cardiomyopathy. Circulation 2003, 107:798-802.
22. El-Adawi H., Deng L., Tramontano A., et al. The functional role of the JAK-STAT pathway in post-infarction remodeling. Cardiovasc Res 2003, 57:129-138.
23. Harada M., Qin Y., Takano H., et al. G-CSF prevents cardiac remodeling after myocardial infarction by activating the Jak-Stat pathway in cardiomyocytes. Nat Med 2005, 11:305-311.
24. Butler K.L., Huffman L.C., Koch S.E., Hahn H.S., Gwathmey J.K. STAT-3 activation is necessary for ischemic preconditioning in hypertrophied myocardium. Am J Physiol Heart Circ Physiol 2006, 291:H797-H803.
25. Lecour S., Suleman N., Deuchar G.A., et al. Pharmacological preconditioning with tumor necrosis factor-alpha activates signal transducer and activator of transcription-3 at reperfusion without involving classic prosurvival kinases (Akt and extracellular signal-regulated kinase). Circulation 2005, 112:3911-3918.
26. Boengler K., Buechert A., Heinen Y., et al. Cardioprotection by ischemic postconditioning is lost in aged and STAT3-deficient mice. Circ Res 2008, 102:131-135.
27. Jacoby J.J., Kalinowski A., Liu M.G., et al. Cardiomyocyte-restricted knockout of STAT3 results in higher sensitivity to inflammation, cardiac fibrosis, and heart failure with advanced age. Proc Natl Acad Sci USA 2003, 100:12929-12934.
28. Oshima Y., Fujio Y., Nakanishi T., et al. STAT3 mediates cardioprotection against ischemia/reperfusion injury through metallothionein induction in the heart. Cardiovasc Res 2005, 65:428-435.
29. Obana M., Maeda M., Takeda K., et al. Therapeutic activation of signal transducer and activator of transcription 3 by interleukin-11 ameliorates cardiac fibrosis after myocardial infarction. Circulation 2010, 121:684-691.
30. Beckles D.L., Mascareno E., Siddiqui M.A. Inhibition of Jak2 phosphorylation attenuates pressure overload cardiac hypertrophy. Vascul Pharmacol 2006, 45:350-357.
31. Ruskoaho H. Atrial natriuretic peptide: synthesis, release, and metabolism. Pharmacol Rev 1992, 44:479-602.
32. Izumo S., Nadal-Ginard B., Mahdavi V. Protooncogene induction and reprogramming of cardiac gene expression produced by pressure overload. Proc Natl Acad Sci USA 1988, 85:339-343.
33. Kerkela R., Force T. Recent insights into cardiac hypertrophy and left ventricular remodeling. Curr Heart Fail Rep 2006, 3:14-18.
34. Banerjee I., Fuseler J.W., Price R.L., Borg T.K., Baudino T.A. Determination of cell types and numbers during cardiac development in the neonatal and adult rat and mouse. Am J Physiol Heart Circ Physiol 2007, 293:H1883-H1891.
35. Burger A., Benicke M., Deten A., Zimmer H.G. Catecholamines stimulate interleukin-6 synthesis in rat cardiac fibroblasts. Am J Physiol Heart Circ Physiol 2001, 281:H14-H21.
36. Porter K.E., Turner N.A. Cardiac fibroblasts: at the heart of myocardial remodeling. Pharmacol Ther 2009, 123:255-278.
37. Grotendorst G.R., Duncan M.R. Individual domains of connective tissue growth factor regulate fibroblast proliferation and myofibroblast differentiation. FASEB J 2005, 19:729-738.
38. Collins A.R., Schnee J., Wang W., et al. Osteopontin modulates angiotensin II-induced fibrosis in the intact murine heart. J Am Coll Cardiol 2004, 43:1698-1705.
39. Hirota H., Yoshida K., Kishimoto T., Taga T. Continuous activation of gp130, a signal-transducing receptor component for interleukin 6-related cytokines, causes myocardial hypertrophy in mice. Proc Natl Acad Sci USA 1995, 92:4862-4866.
40. Sano M., Fukuda K., Kodama H., et al. Interleukin-6 family of cytokines mediate angiotensin II-induced cardiac hypertrophy in rodent cardiomyocytes. J Biol Chem 2000, 275:29717-29723.
41. Banerjee I., Fuseler J.W., Intwala A.R., Baudino T.A. IL-6 loss causes ventricular dysfunction, fibrosis, reduced capillary density, and dramatically alters the cell populations of the developing and adult heart. Am J Physiol Heart Circ Physiol 2009, 296:H1694-H1704.
42. Chen M.H., Kerkela R., Force T. Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics. Circulation 2008, 118:84-95.